Clinicopathological and molecular characterization of non–small cell lung cancer with pericardial effusions
Cancer Cytopathology · 2025
DOI: 10.1002/cncy.70015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cytopathology, 2025. Verfasst von Weijie Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, …. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pericardial Effusion. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NCI NIH HHS.
Abstract (Originalsprache)
Background
Cytological evaluation is essential for assessing pericardial effusions (PEs) in non–small cell lung cancer (NSCLC). This study retrospectively examined the clinicopathological, molecular, and prognostic characteristics of patients with NSCLC with PE.
Methods
Clinical data from 80 patients with NSCLC with PE treated at an academic center over the course of 15 years were reviewed. PE specimens were categorized according to the International System for Reporting Serous Fluid Cytopathology (ISRSFC). The analysis included patient demographics, molecular alterations, cytopathology, histology, and survival outcomes.
Results
Of the 80 patients, 36 (45%) were female and 90% had stage IV disease. A smoking history was noted in 58 patients (72.5%), and 22 patients (27.5%) presented with tamponade. Lung adenocarcinoma predominated (87.5%). The ISRSFC categorized 25% of the specimens as negative for malignancy (NFM), 7.5% as atypia of undetermined significance (AUS), 3.75% as suspicious for malignancy (SFM), and 63.75% as malignant (MAL). Immunohistochemistry in 57 specimens identified thyroid transcription factor 1 (65%) as the most frequently positive marker. Molecular analysis revealed p53 mutations (59.1%) as the most prevalent, followed by KRAS (34.1%) and EGFR (15.9%). Kaplan–Meier analysis showed significantly better survival for NFM patients than non‐NFM patients (MAL, SFM, and AUS; p = .0036). Bloody PEs and tamponade were associated with worse outcomes. The immunotherapy group achieved the most prolonged survival among stage IV patients (9.07 months; p = .017). Cox regression confirmed cytology‐negative status as an independent prognostic factor.
Conclusions
Cytological evaluation and ISRSFC classification are crucial for NSCLC‐associated PEs. A multidisciplinary approach integrating cytology, immunohistochemistry, and molecular profiling is essential for optimal management and prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
- Division of Hematology/Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, University of California Davis School of Medicine, Sacramento, California, USA.
ORCID-Profile: Weijie Ma, Tianhong Li, Laura J Tafe, Darcy A Kerr, Xiaoying Liu
Förderung
- BLRD VA
- NCI NIH HHS
Zitieren
APA
Ma, W., Rodrigues Simoes, N. J., Seery, P. P., Li, T., Tafe, L. J., Kerr, D. A., & Liu, X. (2025). Clinicopathological and molecular characterization of non–small cell lung cancer with pericardial effusions. Cancer Cytopathology. https://doi.org/10.1002/cncy.70015
Vancouver
Ma W, Rodrigues Simoes NJ, Seery PP, Li T, Tafe LJ, Kerr DA, et al. Clinicopathological and molecular characterization of non–small cell lung cancer with pericardial effusions. Cancer Cytopathology. 2025. doi:10.1002/cncy.70015
BibTeX
@article{Ma2025,
author = {Ma, Weijie and Rodrigues Simoes, Nathalie J and Seery, Peter P and Li, Tianhong and Tafe, Laura J and Kerr, Darcy A and Liu, Xiaoying},
title = {Clinicopathological and molecular characterization of non–small cell lung cancer with pericardial effusions},
journal = {Cancer Cytopathology},
year = {2025},
doi = {10.1002/cncy.70015}
}
EUVIMED